Status:
TERMINATED
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Advanced Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine whether BMS-986299 both by itself and in combination with Nivolumab and Ipilimumab is safe and tolerable in the treatment of advanced solid tumors. In additio...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed advanced/metastatic solid tumor and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant
- IO therapy resistant or insensitive tumors
- Have at least 2 tumor lesions accessible for biopsy
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
Exclusion
- Primary CNS malignancy
- Participants with other active malignancy requiring concurrent intervention
- Uncontrolled or significant cardiovascular disease
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
April 5 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 14 2022
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT03444753
Start Date
April 5 2018
End Date
February 14 2022
Last Update
May 23 2022
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0003
La Jolla, California, United States, 92093-0698
2
Local Institution
Orange, California, United States, 92868
3
University of California Davis Medical Center
Sacramento, California, United States, 95817
4
Local Institution
New Haven, Connecticut, United States, 06520